Beijing Tiantan Hospital clinical trial pipeline

14 trials changed in the last 30 days: 0 stopped, 8 with notable changes, 6 with minor changes only.

1. Notable

   GRACE · Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment…GRACE · Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD

   Primary completion pushed from Dec 31, 2025 to Oct 30, 2026

   Also in this update: Phase changed: Phase 4 → Phase 2/3; Trial status changed: Unknown → Active, Not Recruiting

   Beijing Tiantan Hospital·Phase 2/3· NCT06495476· Registry history of NCT06495476 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

2. Notable

   DC Vaccine in Recurrent or Progressive High-grade Gliomas

   Primary completion pushed from Jun 30, 2025 to Dec 30, 2026

   Also in this update: Enrollment closed, study ongoing; Study completion pushed from Dec 31, 2025 to Dec 31, 2026

   Beijing Tiantan Hospital·Phase 1· NCT06253234· Registry history of NCT06253234 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

3. Notable

   CAPTAIN · Cilostazol for Preventing Delayed Cerebral Ischemia in…CAPTAIN · Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage

   Primary endpoint(s) modified

   Also in this update: Recruitment opened; Enrollment increased: 316 → 380 participants

   Beijing Tiantan Hospital·Phase 3· NCT07249853· Registry history of NCT07249853 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

4. Notable

   ARTS-SAFE · Advancing Reperfusion Therapy for Ischemic Stroke…ARTS-SAFE · Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment · Acute Ischemic Stroke

   Primary endpoint(s) modified

   Also in this update: Recruitment opened; Primary completion pushed from Sep 30, 2026 to Oct 30, 2026

   Beijing Tiantan Hospital·Phase 2· NCT07423975· Registry history of NCT07423975 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

5. Notable

   Perioperative Multimodal Analgesia for Supratentorial Craniotomy

   Primary endpoint(s) modified

   Also in this update: Recruitment opened

   Beijing Tiantan Hospital·Not applicable· NCT07441421· Registry history of NCT07441421 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

6. Notable

   Myofascial Trigger Points(MTrPs) Injection · Knee…Myofascial Trigger Points(MTrPs) Injection · Knee Osteoarthritis(OA)

   Primary endpoint(s) modified

   Also in this update: Enrollment reduced: 1036 → 238 participants; Study completion moved earlier from Jun 1, 2027 to Jan 1, 2027

   Beijing Tiantan Hospital·Not applicable· NCT07347028· Registry history of NCT07347028 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

7. Notable

   INtensive liPid-lowering Therapy for Acute High-risk IntracRanial…INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

   Primary endpoint(s) modified

   Beijing Tiantan Hospital·Not applicable· NCT07341958· Registry history of NCT07341958 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

8. Notable

   DRBEYOND2 · Drug-Coated Balloon vs Aggressive Medical Management…DRBEYOND2 · Drug-Coated Balloon vs Aggressive Medical Management for High-Risk Symptomatic Intracranial Atherosclerotic Stenosis

   Primary endpoint(s) modified

   Beijing Tiantan Hospital·Not applicable· NCT07830277· Registry history of NCT07830277 on ClinicalTrials.gov (opens the registry)

   Sep 23, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.